| Drug General Information |
| Drug ID |
D04FVD
|
| Former ID |
DCL001019
|
| Drug Name |
TGBA01AD
|
| Drug Type |
Small molecular drug
|
| Indication |
Severe mood disorders [ICD9: 296; ICD10:F30-F39]
|
Phase 2 |
[1]
|
|---|
| Company |
Fabre-Kramer
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C9H12N2O6
|
| Canonical SMILES |
C1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)O
|
| InChI |
1S/C9H12N2O6/c12-3-4-6(14)7(15)8(17-4)11-2-1-5(13)10-9(11)16/h1-2,4,6-8,12,14-15H,3H2,(H,10,13,16)
|
| InChIKey |
DRTQHJPVMGBUCF-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
82889, 112991, 568053, 619611, 5428231, 8151012, 10528503, 11406095, 11436514, 11450975, 24318726, 24439526, 26960018, 41747568, 47173864, 48334698, 57320796, 57694429, 77021583, 81041252, 85090288, 85090305, 85090306, 85174630, 85209586, 88662377, 92298318, 98571051, 103101967, 104296987, 105040738, 117584552, 125326758, 125347576, 125353805, 125372286, 125482517, 125768177, 126666470, 126677767, 127777606, 134339446, 134340665, 136374571, 136913633, 137176496, 142455558, 162090289, 162092615, 162294370
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 1D receptor |
Target Info |
Modulator |
|
|---|
| 5-hydroxytryptamine 1A receptor |
Target Info |
Modulator |
|
|
KEGG Pathway
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Serotonergic synapsehsa04024:cAMP signaling pathway
|
|
Serotonergic synapse
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathway
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Serotonin HTR1 Group and FOS Pathway
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
|
GPCR downstream signaling
|
| References |
| REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. |
|---|
